We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis Looks to Exit Antibacterial, Antiviral Program
Read MoreHide Full Article
As per a statement released by media sources, Novartis AG (NVS - Free Report) is all set to exit its antibacterial and antiviral research program.
The Swiss pharma giant also plans to reduce the headcount at Emeryville, CA, campus of Novartis Institutes for BioMedical Research (NIBR) by about 140.
The company is reportedly in discussions to out-license its preclinical programs as well as antibiotic LYS228. The candidate is being evaluated for the treatment of complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI) in phase II studies.
Per the company, it is in the process of prioritizing its resources in core areas.
The company, however, plans to retain 150 employees in the San Francisco Bay area across the Novartis Institute for Tropical Diseases (NITD) and other functions.
Novartis is not the only company to exit this space, which was once deemed promising. Allergan too is reportedly looking to sell its infectious disease unit. Earlier, in 2016, AstraZeneca (AZN - Free Report) sold its anti-infectives business, primarily outside the United States, to Pfizer (PFE - Free Report) .
Novartis is looking to restructure its business, of late. We remind investors that earlier this month Novartis announced that it intends to spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to grow as a medicines company solely.
The Alcon business wasn’t performing as per management’s expectations. Although it did revive in between, the company decided to spin-off the same in order to focus better on its legacy drug business.
Novartis has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and Kisqali, which continue to boost its sales. However, it is facing the loss of patent protection for some of the key drugs. Consequently, the company has restructured its business and plans to focus on building its portfolio in markets, which promise potential.
Novartis’ shares have declined 2.6% in the year so far compared with the industry’s gain of 1.2%.
Novartis is looking to solidify its presence in the gene therapy space. Earlier, it acquired U.S.-based clinical stage gene therapy company, AveXis, Inc.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Novartis Looks to Exit Antibacterial, Antiviral Program
As per a statement released by media sources, Novartis AG (NVS - Free Report) is all set to exit its antibacterial and antiviral research program.
The Swiss pharma giant also plans to reduce the headcount at Emeryville, CA, campus of Novartis Institutes for BioMedical Research (NIBR) by about 140.
The company is reportedly in discussions to out-license its preclinical programs as well as antibiotic LYS228. The candidate is being evaluated for the treatment of complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI) in phase II studies.
Per the company, it is in the process of prioritizing its resources in core areas.
The company, however, plans to retain 150 employees in the San Francisco Bay area across the Novartis Institute for Tropical Diseases (NITD) and other functions.
Novartis is not the only company to exit this space, which was once deemed promising. Allergan too is reportedly looking to sell its infectious disease unit. Earlier, in 2016, AstraZeneca (AZN - Free Report) sold its anti-infectives business, primarily outside the United States, to Pfizer (PFE - Free Report) .
Novartis is looking to restructure its business, of late. We remind investors that earlier this month Novartis announced that it intends to spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to grow as a medicines company solely.
The Alcon business wasn’t performing as per management’s expectations. Although it did revive in between, the company decided to spin-off the same in order to focus better on its legacy drug business.
Novartis has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and Kisqali, which continue to boost its sales. However, it is facing the loss of patent protection for some of the key drugs. Consequently, the company has restructured its business and plans to focus on building its portfolio in markets, which promise potential.
Novartis’ shares have declined 2.6% in the year so far compared with the industry’s gain of 1.2%.
Novartis is looking to solidify its presence in the gene therapy space. Earlier, it acquired U.S.-based clinical stage gene therapy company, AveXis, Inc.
Zacks Rank
Novartis carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>